Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [937]

I-DXd shows strong brain metastasis responses in extensive-stage small cell...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior...

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC

Professor Martin Wermke - National Center for Tumor Diseases, Dresden, Germany

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC ( Professor Martin Wermke - National Center for Tumor Diseases, Dresden, Germany )

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR...

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR...

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )

ESMO 2025: Latest in EGFR mutant NSCLC

Dr Alfredo Addeo, Prof Nicolas Girard, Dr Anna Minchom and Prof Pascale Tomasini

ESMO 2025: Latest in EGFR mutant NSCLC ( Dr Alfredo Addeo, Prof Nicolas Girard, Dr Anna Minchom and Prof Pascale Tomasini )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in...

Prof Martin Schuler - Essen University Hospital, Essen, Germany

More from ecancer